SCHEMBL347141

SCHEMBL347141

c1ccc(C(OC2CCN(CCCc3nnn[nH]3)CC2)c2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.67
BCHE P06276 9/20 0.51
PARP14 Q460N5 2/20 0.50
SLC6A2 P23975 3/20 0.49
SLC6A3 Q01959 3/20 0.49
CHRM2 P08172 2/20 0.49
HTR1A P08908 2/20 0.49
ADRA2A P08913 2/20 0.49
CHRM1 P11229 2/20 0.49
DRD1 P21728 2/20 0.49
ADRA1A P35348 2/20 0.49
DRD3 P35462 2/20 0.49
KCNH2 Q12809 2/20 0.49
CYP2D6 P10635 2/20 0.49
OPRM1 P35372 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
MAPK1 P28482 2/20 0.48
SLC6A4 P31645 2/20 0.47
MTOR P42345 2/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9055677 0.94 HPGDS (0.60) HPGDSBCHEPARP14SLC6A2SLC6A3
SCHEMBL9053846 0.91 HPGDS (0.56) HPGDSBCHEPARP14DRD3CYP2D6
SCHEMBL21504949 0.88 HPGDS (0.53) HPGDSBCHEPARP14SLC6A2SLC6A3
SCHEMBL21496196 0.80 HPGDS (1.00) HPGDSBCHEPARP14SLC6A2SLC6A3
SCHEMBL3910868 0.80 HPGDS (0.43) HPGDSSLC6A2SLC6A3CHRM2HTR1A
SCHEMBL9053324 0.79 P2RX7 (0.55) SLC6A2SLC6A3CHRM2CHRM1ADRA1A
SCHEMBL9031522 0.79 HPGDS (0.54) HPGDSBCHEPARP14DRD3KCNH2
SCHEMBL6620398 0.76 CHRM2 (0.61) HPGDSBCHEPARP14SLC6A2SLC6A3
SCHEMBL4029782 0.76 CHRM2 (0.61) HPGDSBCHEPARP14SLC6A2SLC6A3
SCHEMBL6617728 0.76 BCHE (0.65) HPGDSBCHEPARP14SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9750749-B2 Methods of treating thyroid eye disease UNIVERSITY OF ROCHESTER (US) 2017-09-05 US claimed
US-7238718-B2 Method for treating myolytic disease and method for screening antimyolytic agent OSAKA BIOSCIENCE INSTITUTE (JP) 2007-07-03 US claimed
US-20050272767-A1 Method for treating myolytic disease and method for screening antimyolytic agent OSAKA BIOSCIENCE INSTITUTE AND RIKEN (JP) 2005-12-08 US claimed
US-20050255576-A1 Three-dimensinal structure of prostaglandin d synthase and utilization thereof JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2005-11-17 US claimed
US-20050227984-A1 Drugs for improving the prognosis of brain injury and a method of screening the same TAIHO PHARMACEUTICAL CO., LTD. (JP) 2005-10-13 US claimed
EP-1535629-A1 DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME Japan Science and Technology Agency (JP) 2005-06-01 EP claimed
US-20250195518-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2025-06-19 US disclosed
WO-2025104233-A1 INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER VIB VZW (BE) 2025-05-22 WO disclosed
WO-2025104229-A1 HEMATOPOIETIC PROSTAGLANDIN SYNTHASE (HPGDS) INHIBITION FOR TREATING CANCER VIB VZW (BE) 2025-05-22 WO disclosed
WO-2025104238-A1 INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 2 AS MEANS FOR TREATING CANCER VIB VZW (BE) 2025-05-22 WO disclosed
EP-4488271-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Japan Tobacco Inc. (JP) 2025-01-08 EP disclosed
CN-118765278-A Indazole compounds and pharmaceutical uses thereof 日本烟草产业株式会社 2024-10-11 CN disclosed
WO-2023163140-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF 日本たばこ産業株式会社 2023-08-31 WO disclosed
EP-1598065-A2 Drugs for improving prognosis of brain injury Japan Science and Technology Agency (JP) 2005-11-23 EP disclosed
US-20050255576-A1 Three-dimensinal structure of prostaglandin d synthase and utilization thereof JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2005-11-17 US disclosed
US-20050227984-A1 Drugs for improving the prognosis of brain injury and a method of screening the same TAIHO PHARMACEUTICAL CO., LTD. (JP) 2005-10-13 US disclosed
US-20050222235-A1 Drugs for improving the prognosis of brain injury and a method of screening the same SHIONOGI & CO., LTD. (JP) 2005-10-06 US disclosed
EP-1535629-A1 DRUGS FOR IMPROVING THE PROGNOSIS OF BRAIN INJURY AND A METHOD OF SCREENING THE SAME Japan Science and Technology Agency (JP) 2005-06-01 EP disclosed
EP-0706522-A1 TETRAZOLE DERIVATIVES HAVING ANTIHISTAMINIC AND ANTIALLERGIC ACTIVITY SUMITOMO METAL INDUSTRIES, LTD. (JP) 1996-04-17 EP disclosed
WO-1995001350-A1 TETRAZOLE DERIVATIVES HAVING ANTIHISTAMINIC AND ANTIALLERGIC ACTIVITY SUMITOMO METAL INDUSTRIES, LTD. (JP) 1995-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222235-A1 Drugs for improving the prognosis of brain injury and a method of screening the same HPGDS, PTGDR, PTGDR2 HPGDS 1/4885BCHE 1306/4885PARP14 1866/4885
US-20250195518-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF HPGDS, PTGIS, HPGD HPGDS 1/4885BCHE 1373/4885PARP14 1604/4885
US-20050227984-A1 Drugs for improving the prognosis of brain injury and a method of screening the same HPGDS, PTGDR, PTGDR2 HPGDS 1/4885BCHE 1306/4885PARP14 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.